

### REMARKS/ARGUMENTS

Claims 6-14 have been withdrawn. Applicants reserve their right to file a divisional(s) on withdrawn matter resulting from this restriction requirement.

The Examiner has required restriction under 35 U.S.C. 121 and 372 to the following:

- Group I      Claims 1-5, drawn to a method of treating AMM by administering a 4-pyridylmethyl-phthalazine derivative, or
- Group II     Claims 6-14, drawn to a combination of a 4-pyridylmethyl-phthalazine derivative and a second compound, and compositions and commercial packages thereof.


Also, The Examiner requires election of species for examination purposes.

Applicants elect Group I and elect the species PTK787 without traverse. Claims 1-5 encompass the elected invention.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-2614

  
\_\_\_\_\_  
Gregory C. Houghton  
Attorney for Applicant  
Reg. No. 47,666

Date: 12/5/07